Anti Tumor Necrosis Factor Alpha and Renal Disease in Rheumatoid Arthritis

Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.

BACKGROUND Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Striking similarities exist in the inflammatory and immunologic response in RA and atherosclerosis. Indeed, adhesion molecules and cytokines, tumor necrosis factor (TNF)-alpha in particular, are key mediators of joint inflammation and of vascular dysfunction ...

The neuroendocrine system and rheumatoid arthritis: insights from anti-tumor necrosis factor-alpha therapy.

Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.

During the last two decades fundamental changes have taken place in the treatment of patients with rheumatoid arthritis (RA). The effective establishment of methotrexate as the anchor drug and the introduction of new drugs, in particular anti-tumor necrosis factor (TNF) alpha blockers and the novel biologics have made the goal of remission feasible for plenty of RA patients. However, almost 14-...

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis

INTRODUCTION The aim of this study was to compare the response between subsequent use of anti-tumor necrosis factor α (anti-TNF) agents and biologic disease-modifying anti-rheumatic drugs (bDMARD) with other mechanism of action (MOA) in rheumatoid arthritis (RA) patients with history of anti-TNF treatment as their first bDMARD. METHODS A retrospective chart review was conducted at eight commu...

rheumatoid arthritis: relationship between insulin resistance and disease Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory

Volume 35, no. 2 activity. rheumatoid arthritis: relationship between insulin resistance and disease Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory Bruno Seriolo, Carmela Ferrone and Maurizio Cutolo http://www.jrheum.org/content/35/2/355.citation J Rheumatol 2008;35;355-357 http://www.jrheum.org/alerts 1. Sign up for TOCs and other alerts http://jrheum.com/faq ...